Home News Covid-19

Merck sells stake in Moderna as vaccine gets FDA review

Bloomberg
Bloomberg12/3/2020 07:01 PM GMT+08  • 2 min read
Merck sells stake in Moderna as vaccine gets FDA review
Merck sold its direct equity investment in Moderna during the first half of the fourth quarter.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Merck & Co. said it sold its stake in Moderna Inc., the biotechnology company that’s in the midst of developing a Covid-19 vaccine. The shares of both companies rose.

Merck sold its direct equity investment in Moderna during the first half of the fourth quarter, according to a statement from the US drugmaker on Wednesday. No terms of the sale of the holdings were given.

Shares of Moderna fell by as much as 9% as the US market opened, but the stock recovered quickly and was up 2.5% to US$144.50 ($193.42) at 10:05 a.m. in New York trading. The company’s stock has seen a more-than-sevenfold surge so far this year. Merck’s shares were up 0.42% to US$81.90.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.